MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Herr, A. S.
Right arrow Articles by Rein, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Herr, A. S.
Right arrow Articles by Rein, T.

Vol. 57, Issue 4, 732-737, April 2000

Rifampicin Is Not an Activator of Glucocorticoid Receptor

Alexandra S. Herr, Gabriele M. Wochnik, Marcus C. Rosenhagen, Florian Holsboer, and Theo Rein

Max Planck Institute of Psychiatry, Munich, Germany

Rifampicin, an antibiotic widely used in tuberculosis therapy, is known to exert psychotropic side effects in some patients. Recently, rifampicin has been reported to activate the glucocorticoid receptor (GR) in human hepatocytes. Because there is evidence that increased levels of glucocorticoids may induce cognitive impairment, sometimes culminating in depression, the side effects of rifampicin may result from GR activation in central nerve cells. Therefore, we used reporter gene assays to determine whether rifampicin displays glucocorticoid-like effects in human neuroblastoma SK-N-MC cells or mouse hippocampal HT22 cells. Rifampicin was unable to elicit any detectable transactivation of GR in both cell types, whereas cortisol or dexamethasone led to a potent transcriptional response. Rifampicin was also inactive in the same HepG2 cell line that was originally used to demonstrate the effect of rifampicin on GR. Moreover, rifampicin was unable to compete with dexamethasone for binding to GR. Finally, by blocking the multidrug resistance P-glycoprotein transporter (a xenobiotic extrusion pump) with verapamil or cyclosporin A, we excluded the possibility that the lack of effect by rifampicin was due to its export from the cell. Our results establish that rifampicin does not activate GR, and rule out the hypothesis that the psychotropic side effects of rifampicin treatment are a consequence of GR activation.

Copyright © 2000 by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 Antimicrob. Agents Chemother.Home page
Y. Yuhas, I. Azoulay-Alfaguter, E. Berent, and S. Ashkenazi
Rifampin Inhibits Prostaglandin E2 Production and Arachidonic Acid Release in Human Alveolar Epithelial Cells
Antimicrob. Agents Chemother., December 1, 2007; 51(12): 4225 - 4230.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
J. Rosen and J. N. Miner
The Search for Safer Glucocorticoid Receptor Ligands
Endocr. Rev., May 1, 2005; 26(3): 452 - 464.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
J. Ruegg, F. Holsboer, C. Turck, and T. Rein
Cofilin 1 Is Revealed as an Inhibitor of Glucocorticoid Receptor by Analysis of Hormone-Resistant Cells
Mol. Cell. Biol., November 1, 2004; 24(21): 9371 - 9382.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
M. C. Rosenhagen, C. Soti, U. Schmidt, G. M. Wochnik, F. U. Hartl, F. Holsboer, J. C. Young, and T. Rein
The Heat Shock Protein 90-Targeting Drug Cisplatin Selectively Inhibits Steroid Receptor Activation
Mol. Endocrinol., October 1, 2003; 17(10): 1991 - 2001.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
Z. Dvorak, M. Modriansky, L. Pichard-Garcia, P. Balaguer, M.-J. Vilarem, J. Ulrichova, P. Maurel, and J.-M. Pascussi
Colchicine Down-Regulates Cytochrome P450 2B6, 2C8, 2C9, and 3A4 in Human Hepatocytes by Affecting Their Glucocorticoid Receptor-Mediated Regulation
Mol. Pharmacol., July 1, 2003; 64(1): 160 - 169.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
U. Schmidt, G. M. Wochnik, M. C. Rosenhagen, J. C. Young, F. U. Hartl, F. Holsboer, and T. Rein
Essential Role of the Unusual DNA-binding Motif of BAG-1 for Inhibition of the Glucocorticoid Receptor
J. Biol. Chem., February 7, 2003; 278(7): 4926 - 4931.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
G. A. Abel, G. M. Wochnik, J. Ruegg, A. Rouyer, F. Holsboer, and T. Rein
Activity of the GR in G2 and Mitosis
Mol. Endocrinol., June 1, 2002; 16(6): 1352 - 1366.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Microbiol. Rev.Home page
R. Nau and H. Eiffert
Modulation of Release of Proinflammatory Bacterial Compounds by Antibacterials: Potential Impact on Course of Inflammation and Outcome in Sepsis and Meningitis
Clin. Microbiol. Rev., January 1, 2002; 15(1): 95 - 110.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
P. Schmidt, F. Holsboer, and D. Spengler
{beta}2-Adrenergic Receptors Potentiate Glucocorticoid Receptor Transactivation via G Protein {beta}{{gamma}}-Subunits and the Phosphoinositide 3-Kinase Pathway
Mol. Endocrinol., April 1, 2001; 15(4): 553 - 564.
[Abstract] [Full Text]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 2000 by the American Society for Pharmacology and Experimental Therapeutics